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I. INTRODUCTION
Each year scientists uncover new mysteries, make miraculous discoveries, and
perfect processes that will aid them in curing thousands of debilitating and fatal
diseases. In the past century, several of the most fascinating discoveries were made
in the field of genetic research. For instance, in 1997, scientists cloned a sheep. The
infamous cloned sheep became known as Dolly.
The importance of genetic research today is overwhelming. Although genetic
research presents many legal and ethical concerns, the benefits drastically outweigh
the costs. For instance over 140 million people stand to benefit from human
embryonic stem cell research, including those Americans suffering from Parkinson’s
and Alzheimer’s disease.1
In an attempt to quell the legal and ethical concerns associated with genetic
research, legislation has been developed and several administrative committees have
been formed. The present restraints placed on the field of genetic research by the
Legislature and the administrative committees are sufficient to deal with the legal
and ethical issues raised.
This Note will focus on the medical achievements that have been made, in large
part, because of advances in genetic research. Specifically, this Note will focus on
the genetic advances associated with the Human Genome Project, Gene Therapy,
Genetic Testing, and Human Embryonic Stem Cell Research.
The last year of the twentieth century brought scientists one step closer to the
successful completion of the Human Genome Project.2 The Human Genome Project
is a government-funded project with the underlying goal of sequencing and mapping
the entire human genome.3 Scientists believe that the completion of this project will
aid them in answering many questions associated with diseases currently afflicting
thousands of Americans.4
Additionally, researchers have made significant advances in the science of gene
therapy. Researchers have developed a method referred to as gene replacement
therapy. Through the use of gene replacement therapy researchers will be able to
replace incorrect genetic material contained in a cell with the correct genetic
material.5 In addition to gene replacement therapy, scientists have also discovered a
method of gene therapy that instructs a cell to internally correct a genetic mistake.6
Genetic testing is another area in which scientists have made important advances.
One advance is the availability of genetic testing for familial polyposis and non-

1
Glenn McGee, Bioethics at the End of the 1900’s, at http://www.msnbc.com/
news/336361.asp (website expired) [hereinafter McGee I].
2

See id.

3

H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179.

4

M. Warman, Maps in the Study of Genetic Variation and Human Phenotypes, at
syllabus.cwru.edu [hereinafter Warman I].
5

LYNN B. JORDE ET AL., MEDICAL GENETICS 283 (2d ed. 1999).

6

Lisa
Laurence,
Gene
Therapy
Breakthroughs
Delight
Geneticists, at
http://www.genesage.com/geneletter/0299/genetherapybreakthrough.html (website expired).

2000-01]

GENETIC RESEARCH

123

hereditary ployposis colon cancer.7 Genetic testing is extremely important, because
research has proven that early disease detection can drastically improve the quality
and longevity of life.8
In November 1998, scientists isolated stem cells in early human embryos.9
Researchers feel this discovery will lead them to possible therapies for diseases such
as Parkinson’s and Alzheimer’s.10 Furthermore, scientists feel that they will be able
generate human organs from isolated stem cells.11 This development will enhance
the therapeutic advantages of transplantation science. Those individuals drastically
in need of organ transplants will no longer have to wait for an organ. With the
ability to generate organs, doctors can help more patients, and significantly reduce
the number of deaths associated with the unavailability of organs for use in
transplantation surgeries.
In addition to discussing the benefits of genetic research, this Note will outline
some of the ethical and legal concerns associated with the field of genetic research.
The most prevalent concerns associated with advances in genetic research center
around the availability of genetic information and how this information will effect
privacy rights and employment and insurance practices. There are several other
concerns and many other benefits associated with genetic research; however, this
Note does not encompass them. The availability of genetic information has caused
people to become concerned about their privacy.12 Additionally, individuals are
concerned about how genetic information will be used by insurance providers in
determining insurance coverage.13 Similarly, the use of genetic information in
employment practices presents another concern associated with the availability of
genetic information.14
There are special concerns associated with human embryonic stem cell research.
Stem cells are isolated from human embryos.15 Therefore, a major controversy
associated with human embryonic stem cell research is the destruction of potential
human life.16 A secondary concern is that human embryonic stem cell research will
encourage women to have abortions.17 This Note will demonstrate how both of these
concerns are unwarranted.
7
Monique K. Mansoura & Francis S. Collins, Medical Implications of the Genetic
Revolution, 1 J. HEALTH CARE L. & POL’Y 329, 341 (1998).
8

Id.; Louis J. Elsas II, A Clinical Approach to Legal and Ethical Problems in Human
Genetics, 39 EMORY L.J. 811, 825 (1990).
9

McGee I, supra note 1, at 2.

10

Id.

11

Id.; Dorthy C. Wertz, Human Embryonic Stem Cells: A Source of Organ Transplants, at
http://www.genesage.com/geneletter/0299/humanembryonicstemcells.html (website expired).
12

H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179.

13

Id.

14

Id.

15

Wertz, supra note 11.

16

Id.

17

Id.
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Even though there are some ethical and legal issues associated with genetic
research, further restrictions should not be placed on the field. This Note will
discuss how the present limitations placed on the field of genetic research, by the
Legislature and administrative committees, are sufficient to effectively suppress the
aforementioned ethical and legal concerns.
The Genetic Privacy Act and the Genetic Privacy and Non-Discrimination Act
have been developed to address the issues previously raised.18 The Americans with
Disabilities Act is broad enough to cover concerns about the use of genetic
information in employment practices.19 The Health Insurance Portability and
Accountability Act of 1996 addresses problems associated with the use of genetic
information by insurance providers.20
Additionally, several committees have been developed to specifically address the
issues raised by genetic research. For example, the National Institute of Health and
the Department of Energy developed the formal Ethical, Legal and Social Issues
[hereinafter “ELSI”] programs.21 These administrative committees are responsible
for making policy recommendations to federal and state legislatures.22
The benefits of genetic research clearly outweigh the costs. The present
limitations placed on the field, by the Legislature and administrative committees, are
sufficient to effectively quash the concerns.
II. SCIENTIFIC BACKGROUND
The study of genetics dates back to the discovery of the human chromosome in
1870.23 Following this important discovery, scientists determined that most human
traits were heritable.24 By the early twentieth century, Gregor Mendel developed his
law of inheritance.25 This law of inheritance became known as Mendelian
inheritance.26 With the development of Mendelian inheritance, the term “gene” was
used to define the fundamental unit of heredity.27

18

George J. Annas, et al., The Genetic Privacy Act and Commentary (1995), at
http://www.ornl.gov/hgmis/resource/privacy/privacy1.html; Michael M. J. Lin, Conferring a
Federal Property Right in Genetic Material: Stepping into the Future with the Genetic
Privacy Act, 22 AM. J.L. & MED. 109, 127, 129 (1996).
19

Mansoura, supra note 7, at 344; Anne Lawton, Regulating Genetic Destiny: A
Comparative Study of Legal Constraints in Europe and the United States, 11 EMORY INT’L L.
REV. 365, 398-404 (1997).
20

Mansoura, supra note 7, at 344.

21

H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179 (Leg. Hist.).

22

Mansoura, supra note 7, at 344.

23

M. Warman, Human Genetics, at syllabus.cwru.edu [hereinafter Warman II].

24

Id. at 3.

25

Id.

26

Id.

27

Id.
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Expanding on Mendelian inheritance, Oswald Avery discovered that
deoxyribonucleic acid or DNA is the chemical basis for inheritance.28 The unveiling
of DNA as the chemical basis for inheritance encouraged scientists to ascertain the
structure of this molecule. James Watson and Francis Crick eventually unearthed the
structure of DNA.29 Watson and Crick determined that the structure of this molecule
represented a winding ladder.30 Therefore, the structure of DNA became known as a
“double helix.”31
Each prong of the winding ladder represents a gene and is composed of
nucleotides.32 There are four nucleotides that make up a DNA sequence:33 adenine,
guanine, cytosine, and thymine.34 The nucleotides are held together by weak bonds,
and once bonded they become known as base pairs.35 Base pairs consist of adeninethymine bonds and guanine-cytosine bonds.36 The organization of these base pairs
delineates the type of information a gene or piece of DNA will carry.37
Once scientists codified DNA as the chemical basis for inheritance and
determined that genes are the fundamental unit of heredity, the term “genome” was
coined to refer to the total amount of genes and DNA found within an organism.38
Scientists have yet to determine exactly how many genes are in the human genome;
however, researchers estimate the number to be between 75,000 and 100,000.39
After scientists came to understand the process of heredity, they moved on to
more fascinating topics. Researchers began to ascertain why disease affects certain
individuals and not others. Additionally, research established that all genetic
disorders and many other diseases result from a mutation or change within the DNA
sequence of a genome.40 This change or mutation can be dramatic or slight.41 Genes
are comprised of base pairs, and scientists estimate that there are approximately three
billion base pairs in the human genome.42 Consequently, there are about three billion
genetic loci that can be mutated.43 Because researchers have concluded mutations
28

Warman II, supra note 23, at 3.

29

Id.

30

Id.

31

Id.

32

H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179.

33

Id. (a DNA sequence is composed of several genes).

34

Id.

35

Id.

36

Id.

37

H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179.

38

Warman II, supra note 23, at 3.

39

Id.

40

Id.

41

Id.

42

Id.

43

Warman II, supra note 23, at 3.

126

JOURNAL OF LAW AND HEALTH

[Vol. 15:121

are the root of many debilitating and fatal disorders, one can see the vast importance
of enhanced genetic research.
III. BENEFITS OF GENETIC RESEARCH
A. The Human Genome Project
Every individual carries at least twenty harmful genes.44
Until recent
developments in genetics, physicians have been unable to identify these harmful
genes.45 Recognizing this immense problem, Congress developed the Human
Genome Project. The Human Genome Project is federally funded and operated
jointly by the National Institutes of Health and the Department of Energy.46 Because
of the medical and scientific importance of this project, Congress apportioned
approximately $3 billion, or about $200 million per year for fifteen years to aid in its
completion.47
The ultimate goal of the Human Genome Project is to sequence, map, and decode
the entire human genome. Researchers are striving to reach this goal by creating
comprehensive linkage maps, disease maps, gene maps, physical maps, radiation
hybrid maps, and body maps.48 Scientists believe that these maps will prove to be
extremely useful in disease gene discovery.49 Researchers explain that one can look
at a genetic map to determine if other investigators have independently placed a
disease gene in the same region as the corresponding disease locus.50 If the disease
gene is placed in the same region as the disease locus, the gene becomes a candidate
for causing the disease.51 Once the gene is determined to be a disease-causing
candidate, scientists can test the gene to ascertain if it is actually responsible for a
particular disease.52
Through mapping, researchers were able to identify the disease gene responsible
for causing Huntington’s Disease, or HD.53 Huntington’s Disease is believed to
effect an estimated three to eleven out of every 100,000 persons.54 The disease
normally presents itself in patients sixty-years old and older.55 Only five percent of
patients afflicted with Huntington’s Disease present symptoms in the first decade of
44

Aubrey Milunsky, The “New” Genetics: From Research to Reality, 27 SUFFOLK U. L.
REV. 1307, 1310 (1993).
45

Id. at 1310.

46

H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179.

47

Id.

48

Warman I, supra note 4, at 5.

49

Id.

50

Id.

51

Id.

52

Id.

53

Warman I, supra note 4, at 3.

54

Id.

55

Id.
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their lives.56 Huntington’s Disease is an extremely debilitating disease; HD patients
suffer from progressive dementia, involuntary movements, and physchiatric
disturbances.57 Before the HD gene was isolated, physicians lacking conclusive
evidence of a family history of Huntington’s Disease would spend months to years
attempting to determine whether an individual was afflicted with this disease.58 Now
that researchers have identified the disease-causing gene, individuals can be rapidly
diagnosed for HD.59 Rapid diagnosis is not a cure, but it will allow physicians to
improve the patient’s quality of life.
On Monday, June 26, 2000, scientists announced the completion of the first
rough map of the human genetic code.60 Over ninety-seven percent of the human
DNA is now mapped.61 This is an amazing accomplishment, and it was completed
ahead of schedule.
The next step in the Human Genome Project is to identify the individual gene and
the proteins that make up the gene.62 This process will allow geneticists to
understand how the gene functions, why some genes cause disease, and how to
develop therapies and cures for thousands of life-threatening diseases.63
Even though the Human Genome Project is only partially complete, many
disease-causing genes have been placed in the same region as the corresponding
disease locus.64 Obviously, the importance of the Human Genome Project is
immense. Researchers believe that vast amounts of beneficial scientific information
will be gained from this project, and as we all know: “knowledge equals power.”65
Therefore, researchers need the freedom to complete this project.
B. Gene Therapy
Gene therapy is the “genetic alteration of the cells of individuals with genetic
diseases.”66 Gene therapy targets two types of cells: germ cells and somatic cells.67

56

Id.

57

Id. Those patients under twenty years of age present with a rapid progression of
bradykinesia, rigidity, epilepsy, and severe dementia. Warman I, supra note 4, at 3.
58

Milunsky, supra note 44, at 1308.

59

Id.

60

Charlene Cairo, Scientists Complete Genetic Milestone (June 26, 2000), at
http://www.msnbc.com/news/424682.asp.
61

Id.

62

Id.

63

Id.

64

Warman I, supra note 4, at 3.

65

Julia Walsh, Reproductive Rights and the Human Genome Project, 4 S. CAL. REV. L. &
WOMEN’S STUD. 145, 147 (1994).
66

JORDE, supra note 5, at 283.

67

Walsh, supra note 65, at 149.
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Somatic cells include all cells in the body, except sperm and egg cells; whereas germ
cells include only sperm and egg cells.68
Somatic cell gene therapy is the alteration of human somatic cells in order to treat
a specific disorder.69 As previously stated, somatic cells include all body cells,
except sperm and egg cells. Although somatic cells are all inclusive, bone marrow
stem cells seem to be the prime candidates for stem cell gene therapy.70 Somatic cell
gene therapy protocols are currently being tested for a number of disorders.71 Below
is a partial list of diseases for which somatic cell gene therapy is being tested:
Disease

Target Cell

Inserted Gene

ADA deficiency
Hemophilia B
Cystic Fibrosis
Malignant melanoma
Duchenne Muscular Dystrophy
Lung cancer
Brain tumors
Ovarian cancer
AIDS

Bone marrow stem cells
Hepatocytes
Airway epithelial cells
Melanoma tumor cells
Myoblasts
Lung cancer cells
Brain cells
Ovarian cancer cells
Helper T lymphocytes

Adenosine deaminase
Factor IX
CFTR
HLA-B7 gene
Dystrophine
Normal p53
Herpes thymine kinase
Herpes thymine kinase
Dominant negative
retrovirus mutations 72

The most commonly used technique in somatic cell gene therapy is gene
replacement. Gene replacement therapy is the replacement of a missing gene
product by inserting a normal gene product into the cell.73 Geneticists insert the new
genetic material into the cell through the use of a viral carrier.74 This viral carrier
enters the nucleus of the cell and deposits the normal gene product into the cell.75
Researchers explain that even a partially effective gene therapy may provide
significant health benefits.76
Focusing on diseases like hemophilia, cystic fibrosis, and phenylketonuria or
PKU, researchers have developed a technique that prompts liver cells to change their
own DNA sequences.77 Scientists explain that genes are composed of nucleotides,
and that missing even one nucleotide can cause drastic results.78 For instance,
hemophiliacs are missing the nucleotide responsible for directing liver cells to

68

Id.

69

JORDE, supra note 5, at 283.

70

Id.

71

Id.

72

Id.

73

Id.

74

JORDE, supra note 5, at 283.

75

Id.

76

Id..

77

Laurence, supra note 6.

78

Id.
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produce an important blood-clotting protein.79 Like hemophilia, many genetic
disorders are caused by single nucleotide mutations.80
Dr. Clifford Steer of the University of Minnesota Medical School, determined
that the mutation causing hemophilia occurs on the factor IX gene.81 Relying on this
information, Dr. Steer and his team designed a molecule that can travel into the liver
cells of rats.82 Once inside the nucleus of a liver cell, the molecule can direct the
cell’s internal mechanisms to correct the “clotting” nucleotide on the factor IX
gene.83
This special molecule is referred to as “chimeric RNA/DNA
oligonucleotide.”84 Chimeric RNA/DNA oligonucleotide is composed of genetic
material containing a “correction;” the correction mandates the cell to change its
DNA.85
In simpler terms, this special molecule can be compared to a correction key on a
typewriter.86 The molecule alerts the cell to a mistake in its DNA sequence, then the
cell corrects the mistake by “writing over” the incorrect nucleotide or nucleotides.87
In hemophiliacs the factor IX gene has a cytosine, “C,” in place of adenine, “A.”88
Chimeric RNA/DNA oligonucleotide instructs the cell to replace the “C” with an
“A.”89 This molecule has the power to correct, insert, or delete up to three
nucleotides.90
Dr. Steer and his team have also performed a similar procedure to correct the
genetic mutation that causes the rodent equivalent of Crigler-Najjar syndrome.91
Crigler-Najjar syndrome, like hemophilia, affects the liver.92 Children born with this
disease are unable to metabolize the protein billirubin.93 Consequently, these
children suffer from brain damage and will ultimately succumb to an early death.94
The procedure developed by Dr. Steer and his team will assist researchers in creating
therapies to cure and treat the most debilitating diseases, like Crigler-Najjar
syndrome.
79

Id.

80

Id.

81

Id.

82

Laurence, supra note 6.

83

Id.

84

Id.

85

Id.

86

Id.

87

Laurence, supra note 6.

88

Id.

89

Id.

90

Id.

91

Id.

92

Laurence, supra note 6.

93

Id.

94

Id.
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A major difference between Dr. Steer’s method and traditional gene therapy is
the use of a chimeric RNA/DNA oligonucleotide in the place of a viral carrier to
deliver the genetic material to the target cell.95 The procedure developed by Dr.
Steer and his team is referred to as chimeraplasty.96 Chimeraplasty is directed at
somatic cells not germ cells, therefore the results are not heritable.97 Dr. Steer and
his team are confident that chimeraplasty will be used to cure liver-based diseases in
the future.98 Furthermore, Dr. Steer expects this method to be applicable not only to
stem cells found in the liver, but also to those found in the bone marrow, nervous
system, renal system, and the muscular system.99
Another type of gene therapy is germline therapy. Germline therapy involves the
modification of all cells in the body, including those cells that produce gametes.100
Germline therapy affects those cells involved in reproduction, therefore scientists can
alter heritable traits.101 Furthermore, because germline therapy involves gametes, the
alterations made are inheritable.102 Therefore, any changes made through germline
therapy can be passed from the recipient to his offspring.103
The ability of scientists to alter future generations has been the root of much
controversy surrounding gene therapy. Many argue that researchers should not be
able to change the traits of an individual prior to birth, without his consent. Putting
this controversy aside, germline therapy is essential to the early treatment of genetic
disorders.104
Although no one has been cured by gene therapy as of yet, researchers explain
that this genetic advancement has had some positive effects on individuals afflicted
with many diseases.105 Even though criticism surrounds the area of gene therapy,
research illustrates that this procedure may be the most effective treatment available
for many human diseases.106
C. Genetic Testing
There are three main types of genetic tests available today: screening tests,
diagnostic tests, and predictive or pre-symptomatic tests.107 With the increasingly
95

Id.

96

Id.

97

Laurence, supra note 6.

98

Id.

99

Id.

100

JORDE, supra note 5, at 287. Gametes are sperm egg cells. Id.

101

Id.; see also Walsh, supra note 65, at 149.

102

Walsh, supra note 65, at 149.

103

Id.

104

Id.

105

Id.

106

Id.

107

M. Warman & S. Schwartz, Genetic Testing, at syllabus.cwru.edu [hereinafter Warman

III].
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large number of diseases afflicting individuals today, genetic testing has become
extremely important.
Genetic screening is used to classify seemingly healthy individuals who are at
risk for the developing diseases.108 Newborn screening is used to determine whether
a newborn is afflicted with or is a carrier of a particular disease.109 Normally this
procedure is done within the first twenty-four to seventy-two hours of life.110
Newborn screening allows physicians to begin treatment early, thereby, adding years
and quality to an individual’s life.
Newborn screening has proven to be extremely effective in treating many genetic
disorders. Phenylketonuria is a genetic disorder that can be controlled through diet if
caught early.111 PKU causes mild to severe mental retardation in-patients afflicted
with this disease.112 The symptoms of PKU resemble developmental delay, therefore
it is difficult for physicians to detect.113 If a newborn is screened for PKU and tests
positive, physicians can regulate the child’s diet.114 Research has shown that
beginning a low phenyalanine diet, before four weeks of age, is highly effective in
altering the course of this disease.115 In fact, individuals on this diet can expect to
develop normal intelligence.116 Newborn screening is essential in the early detection
and treatment of diseases, like PKU.
Carrier screening is used to determine what members of a population are carriers
of genetic disorders.117 Carrier screening gives physicians the ability to determine
whether an individual is a carrier of a disease-causing gene. If an individual is found
to be a carrier of a disease-causing gene, doctors can make counseling
recommendations.118 Furthermore, carrier screening can alert potential parents that
they may pass a disease gene to their offspring.119 Carrier screening is a tool that
assists doctors in ensuring that dangerous disease causing genes are not passed into
new generations.
Carrier screening also aids researchers in determining what populations are more
susceptible to a particular disease. Through carrier screening, researchers have
determined that one in twenty-five Caucasians carry the gene for cystic fibrosis,
108

Id. at 2-3.

109

Id.

110

Id.

111

JORDE, supra note 5, at 268 (PKU affects approximately one in 10,000 to 15,000
Caucasian births).
112
Id. (Approximately 95% of patients suffering from PKU who go untreatedwill develop
mild to severe mental retardation.).
113

Id.

114

Id.

115

Id.

116

JORDE, supra note 5, at 268.

117

Id.

118

Milunsky, supra note 44, at 1310-11.

119

Id.
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about one in twelve people of Mediterranean decent carry the gene for thalassemia,
about one in ten African Americans carry the gene for sickle-cell anemia, and about
one in thirty Ashkenazi Jews carry the gene for Tay-Sacs disease.120 Monitoring
disease gene distribution over given populations will allow researchers to determine
why certain individuals succumb to certain diseases.
Although genetic screening tests are medically and scientifically beneficial, they
are not conclusive.121 Once the presence of a disease-causing gene is suspected in an
individual, physicians recommend diagnostic testing.122 Diagnostic testing is used to
confirm the presence of a disease-causing gene.123
In contrast, pre-symptomatic or predictive testing is used on healthy individuals
who may have a family history of disease.124 Pre-symptomatic or predictive testing
is done before the individual presents any signs of a disease.125 Consequently, results
from this method of genetic testing can cause psychological or physical harm.126
This method of testing raises concerns about privacy and confidentiality, in that it is
a method of looking into the future.127 Many fear that predictive or pre-symptomatic
testing will make genetic information available for use by employers, insurance
providers, and health care providers.128 This is a prevalent concern because the
genetic information can forecast the future; therefore insurance providers and
employers can make decisions based on future events.
Many case studies establish that genetic testing can save thousands of lives. For
example, early diagnosis of colon cancer can be life saving. Genetic testing for the
disease-causing gene for colon cancer is now available.129 Patients testing positive
for one copy of the autosomal gene responsible for causing colon cancer can undergo
life saving surgery.130 Surgeons can perform a colonectomy or can remove colon
adenomas before symptoms of the disease become present.131 Both of these
procedures effectively prevent colon cancer.132 In addition to colon cancer, early
diagnosis and treatment are successful tools in the prevention of many other diseases,

120

Id.

121

Warman III, supra note 107, at 3.

122

Id.

123

Id.

124

Id.

125

Id.

126

Warman III, supra note 107, at 3.

127

Milunsky, supra note 44, at 1312.
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Id.
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Id.
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H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179.
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such as PKU.133 Early diagnosis and treatment of disease can eliminate thousands of
needless and painful deaths.
Even though genetic testing raises concerns over privacy, such as genetic
information being disclosed to an unauthorized source, and the use of such test
results by insurance providers and employers, the benefits outweigh the risks. Early
diagnosis and treatment of disease prevents thousands of deaths; genetic testing
assists physicians in this process. In response to the concerns, federal legislation has
been developed to safeguard the privacy of genetic information and to ensure that
employers and insurance providers do not misuse it.
IV. HUMAN EMBRYONIC RESEARCH
Human embryonic research is extremely important in the advancement of
transplantation science. Findings show that in 1997 approximately 56,000 people in
the United States were awaiting organ transplants.134 The United Network for Organ
Sharing explains that approximately 4000 of the 56,000 Americans awaiting organ
transplants died because of the unavailability of organs.135 The decreasing number of
organs available for transplantation has caused bioethicists to suggest paying people
for organ donations.136 In some countries, organ shortages have lead to mandatory
organ donation and the removal of organs from living persons.137
Presently, the problem in the United States has not lead to mandatory organ
donation, but researchers predict that if families do not begin to donate organs of the
deceased, drastic measures will need to be taken.138 Researchers suggest that using
isolated human embryonic stem cells to grow organs may solve this problem.139 At
the present time, researchers are not exactly sure how to create organs from isolated
stem cells, but they expect to know in the near future.140 Once scientists determine
how to make organs from isolated stem cells, organs will be readily available for
transplantation, and thousands of deaths will be prevented.141
A. Benefits of Human Embryonic Research
Although human embryonic research has sparked a significant amount of
controversy, many positive scientific and medical advances have been made in the
field. Possibly the most significant advancement is the isolation and growth of
embryonic cells that are capable of developing into organs.142 Human embryonic
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stem cells can develop into many different organs when given the proper genetic
instructions.143
On November 6, 1998, the New York Times reported that two research groups,
one headed by Dr. James A. Thomson of the University of Wisconsin, Madison and
the other headed by Dr. John Gearhart of Johns Hopkins University, Baltimore,
succeeded in growing human stem cells in a laboratory.144 Many hope that
researchers will be able to use these stem cells to generate human organs.145
The research groups isolated the human embryonic stem cells using two different
procedures. Dr. Thomas’ group removed stem cells from a fifteen to twenty cell
“pre-embryo” called a blastocyst.146 The stem cells were taken from the blastocysts
approximately three days after fertilization.147 At this stage, each stem cell has the
potential to become many different parts of the body, and is referred to as
pluripotent.148 During the blastocyst stage these stem cells are identical, therefore it
is impossible to determine whether a particular cell will become an embryo or a
placenta.149
Dr. Gearhart and his research team isolated stem cells from the germ cells of
aborted fetuses.150 Unlike other embryonic cells, germ cells are not committed to
becoming a particular organ.151 Therefore, scientists can use genetic material to
instruct the isolated stem cell to develop into any organ.152 Regardless of the method
of isolation, researchers believe that the isolated stem cells are identical, and will be
extremely useful in advancement of transplantation science.153
B. Concerns Associated With Embryonic Stem Cell Research
A major concern associated with human embryonic stem cell research, involving
the first method of isolation, is the destruction of potential life.154 Responding to
this argument, researchers remind critics that three-day old blastocysts used in the
isolation process are not yet embryos.155 At the blastocyst stage, the likelihood that a
particular stem cell will become part of the placenta, which will be discarded at birth,
is equivalent to the likelihood that the same stem cell will develop into part of a
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potential person.156 Many ethics committees, including those in the United States
(the National Institutes of Health and the Human Embryo Research Panel), the
United Kingdom, Australia, and Denmark, have referred to human embryos up to
fourteen days old as “pre-embryos.”157 These committees recognize that before
fourteen days there is absolutely no possible way to differentiate between the cells
that will become part of the embryo and the cells that will become part of the
placenta.158 Therefore, these countries have approved human embryonic research on
“pre-embryos” up to fourteen days old.159
Another major concern associated with human embryonic stem cell research
centers around the second method of isolation. Critics of human embryonic stem
cell research feel the second method of isolation will encourage women to have
abortions.160 This concern is completely unfounded. The request for the donation of
an aborted fetus is made only after the abortion procedure has been completed.161
Second, the woman does not receive any compensation for the donation of an
aborted fetus.162 The argument that this method of stem cell isolation causes abortion
is as ridiculous and unfounded as arguing that organ transplantation causes
murder.163 Scientists and supporters of human embryonic stem cell research suggest
that those who oppose such research should view it as saving a life rather than
ending a life.164
Finally, the Supreme Court of the United States has determined that a fetus is not
a “person” under the Constitution.165 Therefore, a fetus is not afforded any
Constitutional rights.166 Additionally, in Roe v. Wade, the Supreme Court upheld a
woman’s right to receive an abortion.167
In 1995, due to enormous public pressure, Congress instituted a ban on the use of
federal funds in human embryonic research.168 On January 19, 1999, the Department
of Health and Human Services ruled that embryonic stem cells do not fall under the
1995 Congressional ban on the use of federal funds in support of embryonic
research.169 Recognizing the tremendous scientific and medical importance of
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human embryonic stem cell research, Congress concluded that the benefits
outweighed the concerns.170 Consequently, Congress now permits federal funds to
be used in support of human embryonic stem cell research projects.171
The importance of human embryonic stem cell research in the advancement of
transplantation science is tremendous and clearly outweighs the concerns associated
with this type of research. The isolation of stem cells has given scientists the ability
to ensure that in the future persons in need of organ transplants will not die waiting
for an organ. This discovery does not solve all the problems associated with organ
transplants, although it has enabled scientists to look positively on the future of
transplantation science. Additionally, researchers feel that human embryonic stem
cell research will revolutionize the treatment of degenerative diseases like
Parkinson’s, Alzheimer’s, diabetes, heart disease, stroke, arthritis, birth defects,
osteoporosis, spinal cord injuries, burns, and most cancers.172 Ultimately, over 140
million Americans stand to benefit from human embryonic stem cell research
therefore scientists need the freedom to continue their research.173
V. ETHICAL AND LEGAL CONCERNS ASSOCIATED WITH GENETIC RESEARCH
The advances in genetic research are extremely important in the treatment and
diagnosis of disease. However, genetic research has raised some ethical and legal
concerns. The advances in the field of genetics have made vast amounts of personal
genetic information available. The availability of genetic information is the center of
the debate over restrictions on genetic research. Proponents of strict limitations on
genetic research argue that the availability of genetic information can lead to
breaches of privacy and fair employment and insurance practices. Although these
concerns are prevalent in the minds of most people, the current legislation
encompasses all of these concerns.
A. Privacy and Genetic Research
The most compelling concern associated with advances in genetic research is the
effect on privacy rights. The purpose of the Human Genome Project is to gain
access to information locked in an individual’s genetic code.174 Many people believe
this information is so personal, it should stay locked.175 Access to this personal
genetic information will assist researchers in the detection, treatment, and prevention
of disease.176 Recognizing the highly personal and sensitive nature of this
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information, researchers agree it should be afforded special protection to ensure the
individual donor’s privacy interests are not compromised.177
People fear that once scientists unlock the genetic code, anyone will be able to
gain access to this highly personal and sensitive genetic information.178 Genetic
information is the pathway into an individual’s future, past, and present.179 Genetic
information discloses a person’s traits, disease patterns and family history.180
Consequently, if this information is not kept private, the wrong person could gain
access into an individual’s future, past, and present.181
Genetic information is considered to be highly sensitive and private for several
reasons. First, the information contained in a genetic code is largely unknown by the
person in whose genetic material it was found.182 Therefore, if the wrong person
gained access to this information, he would know more about the owner of the
genetic material than the owner knows about himself.183 Second, genetic information
discloses probabilistic health information about the individual’s family, especially
parents, siblings, and children.184 Finally, because the DNA molecule is stable, once
stored, it can become an infinite source of genetic information.185
Because genetic material contains highly sensitive and personal genetic
information, many fear that once it becomes available the donor’s privacy rights will
be violated. Although this is a valid concern, legislation has been developed to
ensure that Americans do not have to sacrifice their Constitutionally protected right
to privacy for advances in genetics. The Genetic Privacy Act and the ELSAI
Program have been developed to protect this privacy interest.
B. Employment Practices and Genetic Research
Another issue raised by genetic research is the use of genetic information in
employment practices. Critics of the availability of genetic information believe that
genetic test results and information will be used unfairly in employment practices.186
Some fear that a discouraging genetic makeup will eliminate them from the job
market.187 Furthermore, people fear that employers will begin to use genetic tests to
screen employees for genetically desired or undesired traits.188 Finally, many fear
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that negative genetic information will cause their employer to deny them insurance
coverage.189
There is some evidence that genetic information has been the basis for denying
corporate insurance coverage. For example, the father of an eight-year old girl
suffering from PKU had a family group insurance plan through his employer.190 The
young girl’s medical records indicated that she was on a low phenylalanine diet and
was developing normally and healthy.191 Subsequent to her diagnosis, her father
changed jobs and was denied insurance coverage by his new employer, because of
her condition.192
The issues associated with the use of genetic information in employment
practices are significant; however, federal legislation has been developed to ensure
that these issues are dealt with effectively. For instance, in 1995 the Equal
Employment Opportunity Commission broadened the Americans with Disabilities
Act to address concerns raised by the use of genetic information in employment
practices.193 Furthermore, many committees have been developed to ensure that
employers do not abuse the availability of genetic information.194
C. Insurance Coverage
The availability of genetic information has fueled concerns that it will be used by
insurance providers in making coverage decisions.195 Insurance coverage is based on
a theory of shared risks.196 Therefore, prior to offering coverage, an insurance
company will appraise all potential risks of the individual or the group.197 Some of
the risk factors used in coverage selection are age, present health, and the potential
for future disease.198 The presence of certain health conditions can result in higher
premiums or complete denial of coverage.199 Fortunately, most health conditions
develop later in life; therefore people afflicted with these conditions can secure
insurance coverage, at a reasonable rate, prior to the detection of the disease.200
The availability of genetic information has the potential to change the way in
which insurance providers determine coverage.201 First, genetic tests will enable
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physicians to determine the presence of a disease prior to the onset of symptoms.202
Insurance providers may see the presence of a potential disease as too great a risk.203
Therefore, they may begin to deny coverage or charge extremely high premiums to
people who are not sick and who may never become sick.204
There are several cases involving individuals who have been denied insurance
coverage based on their genetic makeup. A woman who questioned her gynecologist
about a family history of Huntington’s Disease was denied coverage.205 Likewise a
salesman with a mild, stable, barely perceptible genetic characteristic was denied
insurance coverage.206 A family was excluded from coverage when their insurance
provider discovered that the son suffered from a form of genetic mental
retardation.207 The insurance provider denied coverage to the entire family, even
though it knew that the genetic disorder did not affect his health and was unlikely to
be present in any of the female family members.208 Although these cases are
disturbing, evidence establishes that insurance providers rarely use genetic
information to determine whether or not to provide an individual or group with
insurance coverage.209
The concerns associated with the use of genetic information by insurance
providers are significant; however, federal legislation has been developed to curb
this problem. In 1996, the Health Insurance Portability and Accountability Act was
passed to ensure that insurance providers do not make coverage decisions based on
genetic information.210 Focusing on the use of genetic information by insurance
providers, the House of Representatives recently enacted the Genetic Privacy and
Nondiscrimination Act.
Additionally, the National Institute of Health, the
Department of Energy Working Group, and the National Action Plan on Breast
Cancer working jointly have made a series of policy recommendations on the use of
genetic information and insurance coverage for federal and state legislatures.211
VI. FEDERAL LEGISLATION
In response to the aforementioned concerns, several pieces of legislation have
been developed and amended. The Genetic Privacy Act was created to deal with the
privacy issues associated with the availability of genetic information.212 Congress
recently enacted the Genetic Privacy and Nondiscrimination Act to restrict the use of
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genetic information by insurance and health care providers and in employment
practices.213 The Equal Employment Opportunity Commission broadened the scope
of the Americans with Disabilities Act, thereby prohibiting employers from misusing
genetic information.214 The Health Insurance Portability and Accountability Act was
enacted to ensure the fair use of genetic information by insurance providers.215 The
present legislative restrictions on the use of genetic information are ample enough to
overcome the current problems associated with genetic research.
A. The Genetic Privacy Act
The Genetic Privacy Act [hereinafter “GPA”] has three common goals. First, the
GPA seeks to encourage a greater dissemination of information to patients and
donors of genetic material.216 Second, the GPA assures the protection of genetic
information, while promoting continued research and experimentation in the field of
genetics.217 Finally, the GPA encourages individuals to supply genetic samples for
analysis and research.218
The underlying goal of the GPA is to protect the sample source’s219 interest in his
own genetic material and information.220 The drafters of the GPA also realize the
importance of continued genetic research in the discovery and treatment of
disease.221 Therefore, the GPA takes the proper steps to protect the sample source’s
interest in his genetic material without discouraging continued advancements in
genetics.
1. The GPA Adequately Monitors the Collection, Analysis and Disclosure
of Genetic Material.
Sections 101(a) and 102(a) of the GPA prohibit the collection and genetic
analysis of an individually identifiable DNA sample without the written consent
from the sample source or a representative of the sample source.222 Section 103(a) of
the GPA outlines the requirements for a valid written authorization for the collection
and analysis of a DNA sample.223 Pursuant to Section 103(a) of the GPA, a valid
authorization contains the following: 1) a writing signed and dated by the sample
source or the sample source’s representative; 2) the identity of the individual
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collecting or requesting the genetic sample; 3) the identity of the facility where the
DNA sample will be analyzed and stored; 4) the manner in which the DNA will be
collected; 5) a description of all authorized uses of the DNA sample; 6) a statement
regarding storage of the DNA after completion of the genetic analysis; and, 7) a
provision that permits the sample source or sample source’s representative to
prohibit the use of the DNA sample for research or commercial purposes.224 The
GPA provides for an extremely strict written authorization requirement for the
collection and analysis of a DNA sample.225 This written authorization requirement
allows for enhanced dissemination of information from the researcher to the patient,
sample source, or the sample source’s representative.226 Furthermore, §§ 101, 102,
and 103 ensure that the sample source or the sample source’s representative has
complete control over the DNA sample.227
Section 111(a) of the GPA prohibits any person from communicating or
disclosing private genetic information without written authorization from the sample
source or a representative of the sample source.228 Section 112(a) of the GPA
provides that a valid disclosure authorization contains the following: 1) a writing
signed and dated by the sample source or a representative of the sample source; 2)
the identity of the individual granting the authorization and the individual’s
relationship to the sample source (if not sample source); 3) the identity of the person
permitted to make the disclosure; 4) a description of the specific genetic material to
be disclosed; 5) the identity of the person to whom the information is to be disclosed;
6) a description of the purpose for disclosure; 7) the date upon which the
authorization expires (cannot be longer than thirty days after grant of authorization);
and, 8) a statement that the sample source or sample source’s representative can
revoke the authorization at any time.229
Analogous to §§ 101(a) and 102(a) of the GPA, § 111(a) provides a stringent
written requirement for the disclosure of genetic information. The written disclosure
requirement ensures the privacy of the sample source by giving him complete control
over the disclosure of his genetic information.230 While protecting the privacy
interest of the sample source, the GPA provides researchers with the flexibility they
need to access a patient’s genetic information.231
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2. The GPA Confers a Federal Property Right in the DNA Sample to
the Sample Source.
Pursuant to § 104(a) of the GPA, the sample source or the sample source’s
representative receives a federal property right in his DNA sample.232 Because the
sample source is the sole owner of his genetic material, he can order the destruction
of the sample at any time.233 The effect of this provision is two-fold. First, § 104(a)
of the GPA protects the privacy interest the sample source has in his genetic
material.234 This privacy interest is protected because the sample source or owner
has complete control over the how the sample will be used. Second, § 104(a) of the
GPA promotes continued developments in genetic research.235 The sample source’s
property right in his DNA sample gives those hesitant about participating in research
projects the incentive to do so.236
3. Effectiveness of the GPA in Dealing with Issues Raised by Genetic Research.
The GPA adequately deals with the privacy concerns associated with advances in
genetic research. The GPA provides a strict written authorization requirement for
the collection, analysis, and disclosure of genetic material. The GPA confers a
federal property right in the DNA sample to the sample source, thereby giving the
sample source complete control over his genetic material. The Genetic Privacy Act
effectively suppresses concerns raised by the advances in genetic research, while
promoting continued research and development in the field of genetics.
B. Genetic Privacy and Nondiscrimination Act of 1999
The Genetic Privacy and Nondiscrimination Act of 1999 [hereinafter “GPNA”]
was passed by the House of Representatives in the 106th Congress.237 The purpose
of the GPNA is to establish limitations on the disclosure and use of genetic
information by insurance providers and employers.238 By restricting the use and
disclosure of genetic information, the GPNA safeguards an individual’s
Constitutionally protected right to privacy.
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1. GPNA Prohibits Health Insurance Discrimination Based on an Individual’s
Genetic Information.
Section 2 of the GPNA amends the Public Health and Service Act [hereinafter
“PHSA”] to prohibit insurance discrimination based on genetic information.239
Additionally, § 2(B) of the GPNA prohibits the use and disclosure of genetic
information without the individual owner’s consent.240 This section amends Subpart
2 of Part A of Title XXVII of the PHSA by adding an additional section. Section
2707 (section added by the GPNA) of the PHSA provides, in pertinent part:
A group health plan, and a health insurer offering health insurance
coverage in connection with a group health plan, may not use genetic
information to reject, deny, limit, cancel, refuse to renew, establish
differential rates on premium payments for, or otherwise affect benefits
provided under the plan or health insurance coverage offered in
connection with the plan.241
Additionally, § 2707 of the PHSA states that a health insurance provider may not
disclose or be compelled to disclose (even through a subpoena) an individual’s
genetic information without specific authorization from the individual or a legal
representative of the individual.242 The authorization must be in writing and must
contain the following: 1) a description of the information to be disclosed; 2) the
name of the individual or entity to which the information is to be disclosed; and, 3)
the purpose of the disclosure.243 The same amendments were made to Subpart B of
part 7 of Title I of the Employment Retirement Income Security Act of 1974.244
The GPNA effectively addresses issues raised about the use of genetic
information by insurance providers. The GPNA does not permit insurance providers
to make coverage decisions based on an individual’s genetic information.
Furthermore, the GPNA prohibits the disclosure of such information without the
expressed written consent of the owner. The GPNA, in accordance with the GPA,
ensures that advances in genetic information will not punish American citizens.
2. The GPNA prohibits the use of Genetic Information in Employment Practices.
Section 3 of the GPNA prohibits the use of genetic information in employment
practices.245 Section 3(a)(1)(A)(B) provides, in pertinent part:
[I]t shall be unlawful employment practice for an employer (A) to attempt
to acquire, to acquire, or to use the genetic information of an employee or
applicant for employment, or (B) to require a genetic test of an employee
or applicant for employment, for the purpose of distinguishing among
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employees or applicants for employment or for the purpose of
discriminating against or restricting any right or benefit otherwise due or
available to an employee or applicant for employment, in connection with
any matter relating to employment or employment opportunities,
including terms and conditions of employment, privileges and benefits for
employees, and termination of employment.246
Section 3 of the GPNA also contains a provision making it unlawful for an
employer to disclose or to allow an unauthorized individual to gain access to
another’s genetic information.247 The GPNA further provides that § 3 of this act is
enforceable under §§ 705-709 of the Civil Rights Act.248
The GPNA adequately addresses concerns regarding the use of genetic
information in employment practices. For all intents and purposes, the GPNA
prohibits the use of genetic information in employment practices.249 In fact, the
GPNA makes the use of genetic information in employment practices illegal.250 The
GPNA is an effective measure enacted by the House of Representatives to suppress
concerns raised by advances in genetics.
C. The Americans With Disabilities Act
On March 14, 1995, the Equal Employment Opportunity Commission
[hereinafter “EEOC”] determined that individuals who are subjected to
discrimination based on genetic information relating to disease or other disorders are
considered disabled.251 Because the EEOC recognizes these individuals as disabled,
they fall under the purview the Americans with Disabilities Act [hereinafter
“ADA”].252 Allowing employees who have been discriminated against based on
their genetic information to bring a cause of action under the ADA will dissuade
employers from misusing genetic information in employment practices.
D. The Health Insurance Portability and Accountability Act
Congress enacted the Health Insurance Portability and Accountability Act
[hereinafter “HIPAA”] in order to address concerns associated with the use of
genetic information by insurance providers.253 HIPAA is codified in various sections
of 26 U.S.C., 29 U.S.C., and 42 U.S.C.254
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Section 1182(a)(1)(E), Title 29 of the United States Code prohibits a health
insurer offering a group insurance plan from establishing rules of eligibility based on
genetic information.255 Section 1182(b)(1) states that an insurance provider offering
a group plan is not permitted to require an individual to pay a higher premium than
those similarly situated, based solely on the individual’s health information.256
Essentially, HIPAA prohibits insurers from using genetic information to deny or
limit health insurance coverage.257 Thus, HIPAA protects many Americans from
losing health insurance coverage based on genetic information, whether it is gained
from genetic testing or medical history.258
HIPAA, in connection with the GPNA, adequately addresses concerns associated
with the use of genetic information by insurance providers. The benefits gained
through genetic research clearly outweigh the concerns, thus the present limitations
placed on the field are sufficient.
VII. PROGRAMS DEVELOPED TO DEAL WITH LEGAL AND ETHICAL CONCERNS
In addition to the federal legislation created to quell the ethical and legal artery
associated with genetic research, several committees have been developed. The
ELSIP and the National Institutes of Health and Department of Energy Working
Groups are two programs that have been created to address the concerns raised by
genetic research.
The United States Department of Energy [hereinafter “DOE”] and the National
Institutes of Health [hereinafter “NIH”] have devoted three to five percent of the
annual Human Genome Budget toward the study of ELSI raised by the availability of
genetic information.259 The main goals of the ELSI programs are to facilitate
medical and scientific research in the field of genetics, while promoting education
and the development of related medical and public policies.260 The ELSI programs
are in place to ensure that genetic information is not misused.261 Specifically, the
ELSI programs focus on maintaining privacy and fair employment and insurance
practices.262 Additionally, ELSI frequently joins with the NIH and the DOE to make
policy recommendations on the importance of protecting genetic information to
federal and state policy makers.263 For example in 1995, the NIH-DOE ELSI
Working Group and the National Action Plan on Breast Cancer developed a series of
policy recommendations to prevent the unfair use of genetic information by
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insurance providers and employers.264
These programs have been created to
safeguard the interests of Americans, and to ensure that individuals do not have to
exchange their rights to privacy, fair insurance and employment practices for
advances in genetic research.
VIII. CONCLUSION
The advances being made in the field of genetics are miraculous. Furthermore,
these advances are extremely beneficial to scientists in the study of disease.
Researchers feel the completion of the Human Genome Project will unlock many
mysteries in the study of human diseases. Although the completion of this project
will lead scientists one step closer to the treatment of thousands of fatal and
debilitating diseases, the project will also make genetic information completely
accessible. Because of the personal and sensitive nature of this information, people
fear that they will lose their right to privacy and to fair employment and insurance
practices. Federal legislation is in place to suppress these concerns.265 Additionally,
programs are in place to make continued policy recommendations to state and
federal policy makers.266 This Note has established that the present limitations
placed on genetic research are sufficient to suppress the concerns associated with this
research. Furthermore, this Note has illustrated that the benefits of genetic research
clearly outweigh those concerns thus scientists should be free to continue their
research without further restrictions.
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